Unesp Informa, 2010, ano 1, n��mero 3

Boletim elaborado pela Assessoria de Comunica����o e Imprensa da Reitoria da UNESP

Unesp Ci��ncia, 2009, ano 1, n��mero 3

Revista elaborada pela Assessoria de Comunica����o e Imprensa da Reitoria da UNESP

ROM-less RNS-to-binary converter moduli {22N ��� 1, 22N + 1, 2N ��� 3, 2N + 3}

In this paper, a novel ROM-less RNS-to-binary converter is proposed, using a new balanced moduli set {22n-1, 22n + 1, 2n-3, 2n + 3} for n even. The proposed converter is implemented with a two stage ROM-less approach, which computes the value of X based only in arithmetic operations, without using lookup tables. Experimental results for 24 to 120 bits of Dynamic Range, show that the proposed converter structure allows a balanced system with 20% faster arithmetic channels regarding the related state of the art, while requiring similar area resources. This improvement in the channel's performance is enough to offset the higher conversion costs of the proposed converter. Furthermore, up to 20% better Power-Delay-Product efficiency metric can be achieved for the full RNS architecture using the proposed moduli set. �� 2014 IEEE.

Projeto de torres met��licas de suporte de cabos de energia el��trica - Aplica����o da parte 3-1 Euroc��digo 3

Mestrado em Engenharia Civil ��� Ramo Estruturas

Fortaleza de Valen��a: ���Projecto de requalifica����o urbana do centro hist��rico de Valen��a���: trabalhos arqueol��gicos: relat��rios de progresso n�� 1, 2, 3, 4 e 5

Relat��rios de Progresso n�� 1, 2, 3, 4 e 5

Polymer electrolyte based on DNA and N,N,N-trimethyl-N-(2-hydroxyethyl)ammonium bis(trifluoromethylsulfonyl)imide

Combining ionic liquids (ILs) with polymers offers the prospect of new applications, where they surpass the performance of conventional media, such as organic solvents, giving advantages in terms of improved safety and a higher operating temperature range. In this work we have investigated the morphology, thermal and electrochemical properties of polymer electrolytes prepared through the addition of con- trolled quantities of the cholinium based IL N,N,N-trimethyl-N-(2-hydroxyethyl)ammonium bis(tri���uo- romethylsulfonyl)imide ([N1 1 1 2(OH)] [NTf2]) to a deoxyribonucleic acid (DNA) host network. These novel IL-based electrolytes have been analyzed aiming at applications in electrochemical devices. An optimized sample showed good thermal stability up to 155 ��C and a wide electrochemical window of ~3.5 V. The highest conductivity was registered for the DNA[N1 1 1 2(OH)][NTf2] (1:1) (2.82 �� 10-5 and 1.09 �� 10-3 S cm-1 at 30 and 100 ��C, respectively).

Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-Aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors

The synthesis and biological evaluation of novel 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3, 4 and 5 as VEGFR-2 tyrosine kinase inhibitors, are reported. The 1-aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 4a-4h, with the arylurea in the meta position to the thioether, showed the lowest IC50 values in enzymatic assays (10-206 nM), the most potent compounds 4d-4h (IC50 10-28 nM) bearing hydrophobic groups (Me, F, CF3 and Cl) in the terminal phenyl ring. A convincing rationalization was achieved for the highest potent compounds 4 as type II VEGFR-2 inhibitors, based on the simultaneous presence of: (1) the thioether linker and (2) the arylurea moiety in the meta position. For compounds 4, significant inhibition of Human Umbilical Vein Endothelial Cells (HUVECs) proliferation (BrdU assay), migration (wound-healing assay) and tube formation were observed at low concentrations. These compounds have also shown to increase apoptosis using the TUNEL assay. Immunostaining for total and phosphorylated (active) VEGFR-2 was performed by Western blotting. The phosphorylation of the receptor was significantly inhibited at 1.0 and 2.5 microM for the most promising compounds. Altogether, these findings point to an antiangiogenic effect in HUVECs.

Assayentwicklung zur Analyse des proteolytischen Abbaus von Abetafibrillen 1-40, 3-40 und pE3-40

Alzheimer ist eine neurodegenerative Erkrankung deren molekulare Ursache, die Anh��ufung von Amyloid-Plaques im Gehirn und die Bildung von Neurofibrillen in den Nervenzellen ist. Grund f��r diese molekularen Ursachen ist das Peptid Amylois beta, welches sich im Gehirn von Alzheimer Patienten anh��uft und zu Fibrillen aggregiert. In der Arbeit wurde untersucht, ob es Unterschiede bez��glich des proteolytischen Abbaus zwischen Abetafibrillen 1-40, 3-40 und pE3-40 gibt und ob die Fibrillen von unterschiedlichen Enzymen abgebaut werden k��nnen. Zudem wurden die Spaltprodukte, die bei diesem Abbau entstanden, miteinander verglichen und analysiert. Es wurde also untersucht, ob die Enzyme eine abbauende Wirkung auf aggregierte A��-Peptide haben und wie sich diese im Vergleich zu den gel��sten Abeta-Peptiden verhalten. Die Untersuchungen fanden mit den Enzymen Neprilysin, Neprilysin 2, Insulysin, Matrix-Metalloproteinasen 2, 3, 9, 13, Plasmin, Plasma Kallikrein, Tissue Kallikrein und Meprin A statt und wurden Mittels MALDO-TOF analysiert.

Contents [and index] to volume 14, numbers 1 to 3, Zoological series / Wilfred H. Osgood.

Fieldiana Zoology v.14, no. 4

Is (1→3)-β-D-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis?

ABSTRACT: Invasive candidiasis is a frequent life-threatening complication in critically ill patients. Early diagnosis followed by prompt treatment aimed at improving outcome by minimizing unnecessary antifungal use remains a major challenge in the ICU setting. Timely patient selection thus plays a key role for clinically efficient and cost-effective management. Approaches combining clinical risk factors and Candida colonization data have improved our ability to identify such patients early. While the negative predictive value of scores and predicting rules is up to 95 to 99%, the positive predictive value is much lower, ranging between 10 and 60%. Accordingly, if a positive score or rule is used to guide the start of antifungal therapy, many patients may be treated unnecessarily. Candida biomarkers display higher positive predictive values; however, they lack sensitivity and are thus not able to identify all cases of invasive candidiasis. The (1→3)-β-D-glucan (BG) assay, a panfungal antigen test, is recommended as a complementary tool for the diagnosis of invasive mycoses in high-risk hemato-oncological patients. Its role in the more heterogeneous ICU population remains to be defined. More efficient clinical selection strategies combined with performant laboratory tools are needed in order to treat the right patients at the right time by keeping costs of screening and therapy as low as possible. The new approach proposed by Posteraro and colleagues in the previous issue of Critical Care meets these requirements. A single positive BG value in medical patients admitted to the ICU with sepsis and expected to stay for more than 5 days preceded the documentation of candidemia by 1 to 3 days with an unprecedented diagnostic accuracy. Applying this one-point fungal screening on a selected subset of ICU patients with an estimated 15 to 20% risk of developing candidemia is an appealing and potentially cost-effective approach. If confirmed by multicenter investigations, and extended to surgical patients at high risk of invasive candidiasis after abdominal surgery, this Bayesian-based risk stratification approach aimed at maximizing clinical efficiency by minimizing health care resource utilization may substantially simplify the management of critically ill patients at risk of invasive candidiasis.

Quarterly analysis of Mental Capacity Act 2005, Deprivation of Liberty Safeguards Assessments (England) Quarters 1 to 3 2009/10

Hospitals and care homes are making use of new measures designed to protect people unable to give consent for their care.The Mental Capacity Act Deprivation of Liberty Safeguards were introduced by law on 1 April 2009 to provide a legal framework for depriving someone of their liberty where they are unable to give informed consent regarding their care. The statistics presented here provide the first official information about authorisations to legally detain a person using the legislation.The safeguards apply to people aged 18 and above who suffer from a mental disorder of the mind (such as dementia or a profound learning disability) and who lack capacity to give consent to the arrangements made for their care and / or treatment. The safeguards cover people in all hospitals and care homes in the statutory, independent and voluntary sectors.A rigorous, standardised assessment and authorisation process is used to ensure only appropriate use is made of the safeguards.Key facts?The number of authorisation requests were: 1,772 in quarter 1 1,681 in quarter 2 and, 1,869 in quarter 3. ?Of the total assessments completed in each quarter, a higher proportion were for females than for males ?For each quarter, around three out of four assessments were made by local authorities while the remaining ones were made by primary care trusts. ?The percentage of authorisations granted leading to someone being deprived of their liberty varied between 33.5 per cent and 50.7 per cent across quarters 1 to 3. ?At 31 December 2009 1,074 people were subject to such authorisations.Quarterly analysis of Mental Capacity Act 2005, Deprivation of Liberty Safeguards Assessments (England) Quarter 1 (0.31MB)Quarterly analysis of Mental Capacity Act 2005, Deprivation of Liberty Safeguards Assessments (England) Quarter 2 (0.31MB)Quarterly analysis of Mental Capacity Act 2005, Deprivation of Liberty Safeguards Assessments (England) Quarter 3 (0.31MB)Have your say - give us your comments on this publication������

New Alzheimer's Association report reveals 1 in 3 seniors dies with Alzheimer's or another dementia

2.3 Million Americans are “Long-Distance Caregivers” for people with Alzheimer’s; Costs for Long-Distance Caregivers are Almost Twice as High.According to the Alzheimer's Association 2013 Alzheimer's Disease Facts and Figures report released today, one in three seniors dies with Alzheimer’s or another dementia in the United States. The new report shows that while deaths from other major diseases, such as heart disease, HIV/AIDS and stroke, continue to experience significant declines, Alzheimer’s deaths continue to rise — increasing 68 percent from 2000-2010.������“Unfortunately, today there are no Alzheimer’s survivors. If you have Alzheimer's disease, you either die from it or diewith it,” said Harry Johns, president and CEO of the Alzheimer’s Association. “Now we know that 1 in 3 seniors dies with Alzheimer’s disease or another dementia. Urgent, meaningful������action is necessary, particularly as more and more people age into greater risk for developing a disease������that today has no cure and no way to slow or stop its progression.”Read more here.������������������������������